Israel HealthCare Ventures (IHCV)- a leading Israeli life sciences venture fund - was founded at the end of the year 2000. The fund is focused on providing funds (capital) to Israeli and Israeli-related companies in the fields of medical devices, pharmaceuticals, biotechnology, nanotechnology and medical-related IT.
IHCV is a venture fund that operates much like a long-term investment company. It pursues a hands-on, personal and informal approach, providing portfolio companies with professional advice, ongoing management support and an extensive network of contacts throughout the global medical and financial arenas.
IHCV’s position within the Israeli VC and healthcare industries fosters a robust deal flow which includes most of the promising opportunities that appear in the market. IHCV is open to investment opportunities across a broad spectrum of possibilities in the life sciences field. The fund is not limited by preset policies that define the stage, discipline or the size of investment. IHCV’s ideal investment opportunity is a company with a superior management team coupled with a truly innovative technology, providing a solution to an existing unmet clinical need. The company should display excellent potential for rapid market acceptance and profitability.
IHCV I the first fund, invested in twelve companies during the years 2001 – 2006. The fund has had five exits so far. IHCV I is profitable and has already made a substantial return to its investors.
IHCV II the second fund has started to invest in May 2006. To date, IHCV II has made thirteen investments in Israeli biotech and medical device companies and had one exit so far. The fund is actively seeking new investments.